2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
02/28/19Nuvectra® Reports Fourth Quarter and Full Year 2018 Financial Results
Record Fourth Quarter & Full Year 2018 Algovita® Sales of $14.1 million and $47.1 million, Up 36% and 84% YoY Respectively PLANO, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the fourth quarter and full year ended December 31, 2018. Recent Highlights Record consolidated revenues of $14.5 million and $48.8 million in the fourth quarter and full year 2018, up 36% an... 
Printer Friendly Version
02/26/19Nuvectra® to Present at 39th Annual Cowen Healthcare Conference
PLANO, Texas, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Fred Parks, PhD, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the upcoming 39th Annual Cowen Healthcare Conference in Boston, Massachusetts. Event:             39th Annual Cowen Healthcare Conference Date:               Tuesday, March 12, 2019 Time:             ... 
Printer Friendly Version
02/19/19Nuvectra to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
PLANO, Texas, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter and full year ended December 31, 2018 on Thursday, February 28, 2019 after market close. Nuvectra will hold a conference call on Thursday, February 28, 2019 at 4:30pm ET to discuss the results. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for internatio... 
Printer Friendly Version
01/31/19Nuvectra® Appoints Dr. Fred B. Parks as Chief Executive Officer
Elects Christopher G. Chavez as a Member of the Board of Directors PLANO, Texas, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced the appointment of Fred B. Parks, PhD, as Chief Executive Officer, effective immediately. Dr. Parks has served as a member of the Company’s Board of Directors since March 2016 and will retain his position as a Director. His appointment follows Scott F. Drees’s decision to step down as ... 
Printer Friendly Version
01/29/19Nuvectra Provides Update on Virtis™ FDA PMA Submission
PLANO, Texas, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a medical device company dedicated to neuromodulation, announced today that the U.S. Food and Drug Administration (FDA) has advised that its review of Company’s pre-market approval (PMA) application for its Virtis Sacral Neuromodulation (SNM) system has been extended beyond the expiration of the FDA’s 180-day review period. Scott Drees, Chief Executive Officer, commented, “FDA has informed us that they have... 
Printer Friendly Version
01/07/19Nuvectra® Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue
PLANO, Texas, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2018. Preliminary unaudited consolidated revenue in the fourth quarter of 2018 is expected to be in the range of $15.3 to $15.7 million, compared to $12.0 million in the fourth quarter of 2017. Preliminary unaudited Algovita revenue in the fourth quarter of 2018 is... 
Printer Friendly Version
01/02/19Nuvectra Announces Divesture of NeuroNexus Subsidiary
PLANO, Texas, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has entered into an agreement effective December 31, 2018, to sell its wholly owned subsidiary NeuroNexus Technologies, Inc. (“NeuroNexus”) to NEL Group, Inc., an entity affiliated with certain former employees of NeuroNexus, for $5.0 million in cash. NeuroNexus will operate as a separate entity following the sale. NeuroNexus designs, manufactu... 
Printer Friendly Version